The economic and societal implications of the underfunding of women’s health finally reached the agenda of the World Economic ...

Six months shy of the PDUFA date for its oral, selective glucocorticoid receptor antagonist relacorilant to treat platinum-resistant ovarian cancer, Corcept Therapeutics Inc. reported a 35% reduction ...

Abbott Laboratories reported fourth quarter sales below expectations before the market opened on Jan. 22, sending the stock down nearly 12% from the prior day's closing. The biggest hits came from ...

Oncogenic KRAS mutations are among the most prevalent driver events in solid tumors, with the KRAS G12D variant constituting the dominant allele in pancreatic ductal adenocarcinoma (PDAC) and a ...

Cancer cells expand through mutations – but not just through mutations. They also change their behavior in the absence of underlying genetic alterations. Such plasticity helps the cells both adapt to ...